Katherine Littrell | Vice President, Investor Relations |
Bruce Cozadd | Chairman and Chief Executive Officer |
Daniel Swisher, Jr. | President and Chief Operating Officer |
Robert Iannone | Executive Vice President, Research and Development |
Michael Miller | Executive Vice President, U.S. Commercial |
Shawn Mindus | Senior Vice President, Financial Planning, Analysis and Strategy |
Brandon Folkes | Cantor Fitzgerald |
Umer Raffat | Evercore ISI |
Gary Nachman | BMO Capital Markets |
Gregg Gilbert | SunTrust Robinson Humphrey |
David Amsellem | Piper Sandler & Co. |
Jason Gerberry | Bank of America Securities |
Ken Cacciatore | Cowen & Company |
Esther Rajavelu | Oppenheimer & Co. Inc. |
Akash Tewari | Wolfe Research, LLC |
Aaron Gal | Sanford Bernstein |
Annabel Samimy | Stifel Nicolaus |
Randall Stanicky | RBC Capital Markets |
Ami Fadia | SVB Leerink |
David Risinger | Morgan Stanley |
Balaji Prasad | Barclays |
Jessica Fye | J.P. Morgan |
Graig Suvannavejh | Goldman Sachs & Co. LLC |
Welcome to the Jazz Pharmaceuticals Plc Full-Year, Fourth Quarter 2019 Earnings Conference Call.
Following an introduction from the company, we will open the call to questions.
I will now turn the call over to Kathy Littrell, Head of Investor Relations at Jazz Pharmaceuticals.
Thank you, Kevin, and thanks to those of you who are joining our investor call. Today, we reported our fourth quarter and full-year 2019 financial results and provided financial guidance for 2020.